Menu Back to Master-Protocols-and-Complex-Innovative-Design

Overview

The evolution of clinical trial designs has accelerated since the onset of the pandemic to meet patient and logistical need. While elements of randomized controlled trials remain a gold standard, clinical trials continue to transform, building on innovations in study design and statistical approaches, as well as regulatory flexibilities, with the promise of bringing new medicines to patients more quickly than ever.

Supported by advancement in clinical trail operations, development of digital technologies along with strong partnerships and collaborations amongst key stakeholders, clinical trials are poised to reach more people and add efficiency to clinical drug development. Master protocol and complex innovative designs continue to provide frameworks that hold enormous promise for engaging patients more productively, increasing overall efficiency and improving successful outcomes.

DIA’s Master Protocols and Complex Innovative Design Meeting will bring together a truly multidisciplinary group of experts in clinical trial planning, execution, and analysis to share and discuss both the common and unique challenges and opportunities in the adoption of master protocols and complex innovative design. Join industry, patient, regulatory agency, other government, and NGO representatives to examine the growing body of knowledge, experience, and resources available to better meet patient needs through successful implementation of innovation in clinical trial designs.




Who should attend?

Professionals and students from industry, academia, and government involved in all phases of the healthcare product lifecycle who are interested in applying new skills and tools to improve program and project execution including:

  • Clinical Data Management
  • Clinical Data Management/eClinical
  • Clinical Research
  • Good Clinical Practice
  • Patient Engagement
  • Research & Development
  • Rare, Orphan Diseases
  • Strategic Planning
  • Statistics

Learning objectives

At the conclusion of this activity, participants should be able to:
  • Articulate the challenges and opportunities for the use of complex innovative design and master protocols
  • Explain how master protocols and CIDs contribute to increased efficiency and other enhancements of medical product research to ultimately accelerate patient access to innovative therapies
  • Describe the purpose, anticipated outcomes, and progress to date of the FDA CID Pilot Program
  • Discuss the views of global regulatory authorities (e.g., FDA, EMA, etc.) on CIDs and their suitability/applicability for clinical research in their respective regions; explore aspects and further opportunities for alignment among global regulatory agencies in regard to CID adoption
  • Examine several examples of master protocol designs, complex adaptive designs, and designs using Bayesian techniques, and discuss their regulatory suitability, potential challenges, and benefits for patients and medical product developers
  • Summarize learnings from the use of master protocols to develop vaccines and therapeutics for COVID-19 and how they apply to developing interventions for other indications

Program Committee

  • Daniel  Millar, MBA
    Daniel Millar, MBA Senior Director, Strategic Business Transformation Quantitative Sciences
    Janssen Research & Development, United States
  • Robert A. Beckman, MD
    Robert A. Beckman, MD Professor of Oncology, Bioinformatics, and Biomathematics
    Georgetown University Medical Center, United States
  • Fanni  Natanegara, PhD
    Fanni Natanegara, PhD Senior Director - Statistics
    Eli Lilly and Company, United States
  • Zoran  Antonijevic, MSc
    Zoran Antonijevic, MSc Vice President, Statistical Consulting
    Abond CRO Inc., United States
  • Michelle  Detry, PhD
    Michelle Detry, PhD Director, Adaptive Trial Execution & Senior Statistical Scientist
    Berry Consultants LLC, United States
  • Kristin  Dolinski
    Kristin Dolinski Deputy Vice President, Science and Regulatory Advocacy
    PhRMA, United States
  • AnnCatherine M. Downing, PharmD
    AnnCatherine M. Downing, PharmD Chief Operating Officer - Lilly Research Laboratories
    Eli Lilly and Company, United States
  • Anne-Marie  Duliege
    Anne-Marie Duliege Chief Medical Officer
    Pancreatic Cancer Action Network, United States
  • Yi  Liu, PhD
    Yi Liu, PhD Executive Director Biostatistics
    Nektar Therapeutics, United States
  • Cristiana  Mayer, DrSc, PhD
    Cristiana Mayer, DrSc, PhD Head of Biostatistics
    Johnson & Johnson Vision, United States
  • Pritibha  Singh, MBA, MSc
    Pritibha Singh, MBA, MSc Global Program Associate Director, Oncology Hematology Development
    Novartis AG, Switzerland
  • Rui (Sammi)  Tang
    Rui (Sammi) Tang Vice President, Global Head of Biometrics
    Servier Pharmaceuticals, United States
Load More

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download